Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SGX523 是选择性的和 ATP 竞争性的MET 抑制剂 (IC50:4 nM)。它对 MET 的选择性其它他蛋白激酶高 1000 倍。它具有抗肿瘤特性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 289 | 现货 | ||
2 mg | ¥ 413 | 现货 | ||
5 mg | ¥ 828 | 现货 | ||
10 mg | ¥ 1,230 | 现货 | ||
25 mg | ¥ 2,450 | 现货 | ||
50 mg | ¥ 3,780 | 现货 | ||
100 mg | ¥ 5,450 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 913 | 现货 |
产品描述 | SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf. |
靶点活性 | MET:4 nM |
体外活性 | SGX523(≥10 mg/kg,2次/天,p.o.)可使预计的GTL16肿瘤生长显著延迟.SGX523(30 mg/kg,2次/天)对U87 mg肿瘤生长的抑制效果较明显,其还延迟H441肿瘤生长,且降低MET自磷酸化水平. |
体内活性 | 纳摩尔浓度的SGX523可抑制MET调节的信号、细胞增殖及迁移,但对依赖其他蛋白激酶(如RON)的信号无抑制作用,即使浓度达到微摩级。SGX523可抑制体内MET,这与其剂量依赖性抑制人类恶性胶质瘤、肺癌及胃癌衍生的移植瘤生长有关,表明上述肿瘤对MET的催化活性有依赖性。SGX-523是c-Met/肝细胞生长因子受体酪氨酸激酶抑制剂,可使MET失活而不能与其他蛋白激酶发生相互作用。SGX523对纯化的MET催化区具有明显的抑制效果,但对与之紧密相关的RON无作用。作为ATP竞争性抑制剂,SGX523对低活性和非磷酸化的MET(MET-KD(0P),Ki: 2.7 nM)亲和力更高。 |
激酶实验 | Kinase assays: Initial rate constants are measured at 21 °C in the presence of 100 mM HEPES (pH 7.5), 0.3 mg/mL poly(Glu-Tyr) peptide substrate, 10 mM MgCl2, 1 mg/mL bovine serum albumin, 5% DMSO, 20 nM MET-KD and various concentrations of ATP and SGX523. Total reaction volumes (20 μL) are quenched with 20 μL Kinase-Glo detection buffer. Luminescence is detected in a plate-reading luminometer and the results are analyzed by nonlinear regression. |
细胞实验 | MDCK cells are seeded at 1 × 103 per well in a 24-well plate and incubated at 37 °C in 5% CO2 for 1 week in MEM and 10% fetal bovine serum. HGF (90 ng/mL) and various concentrations of SGX523 are added and the cells are incubated for another 18 hours (37 °C, 5% CO2 humidified incubator) and visualized. A549 cells are plated in 12-well plates (6 × 104 per well) and incubated to confluence to investigate cell migration. A channel is introduced into the monolayers by scratching with a pipette tip. Various dilutions of compound are added in starve medium in the presence and absence of HGF (90 ng/mL).The wells are checked for cell migration after twenty-fou(Only for Reference) |
分子量 | 359.41 |
分子式 | C18H13N7S |
CAS No. | 1022150-57-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 3.59 mg/mL (10 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.7823 mL | 13.9117 mL | 27.8234 mL | 69.5584 mL |
5 mM | 0.5565 mL | 2.7823 mL | 5.5647 mL | 13.9117 mL | |
10 mM | 0.2782 mL | 1.3912 mL | 2.7823 mL | 6.9558 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
SGX-523 1022150-57-7 Angiogenesis Cytoskeletal Signaling MAPK Tyrosine Kinase/Adaptors Raf p38 MAPK c-Met/HGFR Bcr-Abl inhibit Inhibitor antitumor selective exquisitely MET SGX523 SGX 523 inhibitor